Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.

MLA

Nee, Aisling, et al. “Early Prediction of Stable MR4.5 by Depth of Molecular Response at 6 Months in Patients with Chronic Myeloid Leukemia Treated with Frontline Imatinib.” Leukemia & Lymphoma, vol. 63, no. 1, Jan. 2022, pp. 162–69. EBSCOhost, https://doi.org/10.1080/10428194.2021.1961234.

APA

Nee, A., Lipton, J. H., & Kim, D. D. H. (2022). Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib. Leukemia & Lymphoma, 63(1), 162–169. https://doi.org/10.1080/10428194.2021.1961234

Chicago

Nee, Aisling, Jeffrey H. Lipton, and Dennis Dong Hwan Kim. 2022. “Early Prediction of Stable MR4.5 by Depth of Molecular Response at 6 Months in Patients with Chronic Myeloid Leukemia Treated with Frontline Imatinib.” Leukemia & Lymphoma 63 (1): 162–69. doi:10.1080/10428194.2021.1961234.